Clarity Pharmaceuticals Signs Large-Scale Copper-64 Manufacturing Supply Agreement With Theragenics

MT Newswires Live
03/25

Clarity Pharmaceuticals (ASX:CU6) said it has signed a large-scale manufacturing supply agreement for copper-64 with Theragenics, according to a Wednesday Australian bourse filing.

The company said the agreement relates to Theragenics' 134,000-square-foot production facility near Atlanta, Georgia, which houses 14 cyclotrons for centralized, large-scale copper-64 (Cu-64) production.

The supply agreement is ahead of the anticipated commercial launch of Cu-64-SAR-bisPSMA, subject to successful completion of Clarity's phase three registrational trials and subsequent Food and Drug Administration (FDA) new drug application (NDA) approval, the filing added.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10